SOR-C13 TFA – Purity ?99.18% | GMP Manufacturer

SOR-C13 TFA – Purity ?99.18% | GMP Manufacturer

$2.00

SOR-C13 TFA is a truncated peptide derived from soricidin, acting as a potent TRPV6 calcium channel antagonist (IC?? ~14 nM). It demonstrates anti-tumor activity in models of breast, ovarian, and prostate cancer. Purity ?99.18%, GMP-produced. Laboratory research only.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare
Category:

Description

SOR-C13 TFA is a 13-amino-acid peptide derived from the C-terminus of soricidin, a venom peptide originally found in the northern short-tailed shrew. It functions as a high-affinity, use-dependent antagonist of TRPV6—a calcium channel commonly upregulated in several cancers. By inhibiting calcium influx through TRPV6, SOR-C13 disrupts critical survival pathways in tumor cells, showing potent antitumor efficacy in various preclinical models. In vivo imaging studies demonstrate its ability to target TRPV6-rich ovarian and prostate tumors effectively, providing both diagnostic and therapeutic insights. Manufactured with high purity (?99.18%) under GMP standards, SOR-C13 TFA is ideal for advanced oncology research focused on TRPV6-mediated cancer growth and targeting.


Product Category

Peptide TRPV6 Antagonists — specialized peptides that block calcium influx via TRPV6 channels, used in cancer research and tumor imaging.


Product Specifications

ParameterDetails
Product NameSOR-C13 TFA
SynonymsTRPV6 antagonist peptide, soricidin-derived analog
Purity?99.18% (HPLC)
MechanismTRPV6 calcium channel antagonist (IC?? ? 14 nM)
Functional UseAntitumor research, imaging of TRPV6-overexpressing tumors
AppearanceWhite to off-white lyophilized powder
SolubilitySoluble in aqueous buffers; DMSO compatible
Storage–20 °C; protect from light and moisture
GMP ComplianceYes — GMP-certified manufacturing

Mechanism of Action & Research Applications

SOR-C13 TFA competes at TRPV6 channels, blocking calcium entry into cells that overexpress this channel—commonly seen in cancers such as breast, ovarian, pancreatic, prostate, and colon. Blocking calcium influx disrupts cellular proliferation pathways, induces apoptosis, and inhibits tumor growth. In vivo studies show SOR-C13 binds TRPV6-rich tumors with high specificity, enabling imaging and functional targeting. Additionally, it demonstrates more potent reduction of tumor cell viability compared to cisplatin in preclinical models.


Side Effects (For Research Context Only)

In animal models, SOR-C13 is generally well tolerated. Hypocalcemia was reported in Phase I human trials, typically transient and manageable with calcium and vitamin D supplementation. Other observed adverse effects include transient elevations in liver enzymes or blood pressure parameters at high doses. There were no dose-limiting toxicities or serious adverse events at tested levels.


Logistics Transportation

Your order is fully insured for swift and secure delivery. We provide 100% compensation for any lost, detained, or damaged shipments—guaranteed.


Disclaimer

SOR-C13 TFA is strictly intended for laboratory research use only. It is not approved for clinical, diagnostic, therapeutic, or veterinary applications.

Additional information

Weight0.8 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “SOR-C13 TFA – Purity ?99.18% | GMP Manufacturer”

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare